Meltem Pak
Research Subjects
Research Interests
Meltem Pak has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Arzu Pınarbaşı
Department of Medical Biochemistry , Acıbadem Mehmet Ali Aydınlar University, School of Medicine , Istanbul , Turkey
1 shared publication - Devrim Oz-Arslan
Department of Neuroscience, Graduate School of Health Sciences, Acibadem Mehmet Ali Aydinlar University, 34752 Istanbul, Turkey
1 shared publication - Fehime Benli Aksungar
Biochemistry and Molecular Biology Department, Graduate School of Health Sciences, Acıbadem Mehmet AliAydınlar University, 34752 Istanbul, Turkey
1 shared publication - Murat Kolay
Department of Clinical Biochemistry , Acıbadem Labmed Clinical Laboratories , Istanbul , Turkey
1 shared publication
Latest Publications
- Open Access
- 26 August 2021
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 47 (1) , 41-48
Effects of peroxisome proliferator activated receptor gamma (PPARγ) agonist on fasting model applied neuron cultures
Objectives: Peroxisome proliferator activated receptor gamma (PPARγ) agonists used for the treatment of Diabetes Mellitus (DM), has important roles on the regulation of metabolism including ketogenesis in fasting and low glucose states. Recently PPARγ was proven to have anti-oxidant and anti-inflammatory effects on neuronal cells. Methods: In the present study, effects of pioglitazone (PPARγ agonist) on cell survival, energy metabolism and mitochondrial functions were investigated in glucose deprived fasting model applied SH-SY5Y (ATCC/CRL 2266) cell lines. Before and after pioglitazone treatment; energy metabolites (glucose, lactate, ketone (βOHB), lactate dehydrogenase activity), mitochondrial citrate synthase activity and cell viability were investigated. Results and Conclusions: PPARγ agonist addition to glucose deprived, ketone added neurons provided positive improvements in energy metabolites (p<0.01), mitochondrial functions (p<0.001) and survival rates (p<0.01). Changes in mitochondrial citrate synthase activity, lactate and LDH levels of neuronal cells treated with PPARγ agonist have not been previously shown. Our results suggest, pioglitazone as an effective alternative for the treatment of neurodegenerative diseases especially with the presence of ketone bodies. By clarifying the mechanisms of PPARγ agonists, a great contribution will be made to the treatment of neurodegenerative diseases.
- 26 August 2021
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 47 (1) , 41-48
Open AccessEffects of peroxisome proliferator activated receptor gamma (PPARγ) agonist on fasting model applied neuron cultures
Objectives: Peroxisome proliferator activated receptor gamma (PPARγ) agonists used for the treatment of Diabetes Mellitus (DM), has important roles on the regulation of metabolism including ketogenesis in fasting and low glucose states. Recently PPARγ was proven to have anti-oxidant and anti-inflammatory effects on neuronal cells. Methods: In the present study, effects of pioglitazone (PPARγ agonist) on cell survival, energy metabolism and mitochondrial functions were investigated in glucose deprived fasting model applied SH-SY5Y (ATCC/CRL 2266) cell lines. Before and after pioglitazone treatment; energy metabolites (glucose, lactate, ketone (βOHB), lactate dehydrogenase activity), mitochondrial citrate synthase activity and cell viability were investigated. Results and Conclusions: PPARγ agonist addition to glucose deprived, ketone added neurons provided positive improvements in energy metabolites (p<0.01), mitochondrial functions (p<0.001) and survival rates (p<0.01). Changes in mitochondrial citrate synthase activity, lactate and LDH levels of neuronal cells treated with PPARγ agonist have not been previously shown. Our results suggest, pioglitazone as an effective alternative for the treatment of neurodegenerative diseases especially with the presence of ketone bodies. By clarifying the mechanisms of PPARγ agonists, a great contribution will be made to the treatment of neurodegenerative diseases.